Vilin Bio Med Ltd
VILINBIO NSE
Vilin Bio Med Ltd
HealthcareNSE: VILINBIO Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹64.97 Cr
Volatility
Moderate
P/E Ratio
33.8
EBITDA
₹3.19 Cr
Return on Equity
0.97%
Debt to Equity
0.01
Book Value
₹18.6
52W High
₹54.4
52W Low
₹18.95
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vilin Bio Med Ltd insights
29 extracted metrics + investor summaries across FY20–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company has reduced debt.
- Company is almost debt free.
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -2.92%
- Company has a low return on equity of 3.53% over last 3 years.
Growth Rate
Revenue Growth
176.21% ↗
Net Income Growth
880.00% ↗
Cash Flow Change
102.96% ↗
ROE
36.62% ↗
ROCE
13.73% ↗
EBITDA Margin (Avg.)
-8.15% ↗
Quarterly Results
| Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.95 | 4.1 | 8.21 | 7.65 | 8.16 | 4.49 | 10.32 | 9.66 | 32.6 |
| Expenses | 4.56 | 2.99 | 6.74 | 6.26 | 8.73 | 4.07 | 9.95 | 9.32 | 29.74 |
| Operating Profit | 0.39 | 1.11 | 1.47 | 1.39 | -0.57 | 0.42 | 0.37 | 0.34 | 2.86 |
| OPM % | 7.88% | 27.07% | 17.9% | 18.17% | -6.99% | 9.35% | 3.59% | 3.52% | 8.77% |
| Other Income | 0 | 0 | 0.02 | 0.11 | 0.22 | 0.22 | 0.25 | 0 | 0 |
| Interest | 0.25 | 0.32 | 0.33 | 0.38 | 0.41 | 0.41 | 0.44 | 0.07 | 0 |
| Depreciation | 0.11 | 0.08 | 0.08 | 0.08 | 0.05 | 0.07 | 0.03 | 0.07 | 0.21 |
| PBT | 0.03 | 0.71 | 1.08 | 1.04 | -0.81 | 0.16 | 0.15 | 0.2 | 2.65 |
| Tax % | 33.33% | 21.13% | 35.19% | 25.96% | -25.93% | 18.75% | 33.33% | 25% | 32.83% |
| Net Profit | 0.02 | 0.55 | 0.69 | 0.77 | -0.61 | 0.12 | 0.1 | 0.15 | 1.78 |
| EPS in Rs | 0.06 | 1.67 | 0.69 | 0.55 | -0.44 | 0.09 | 0.07 | 0.11 | 1.17 |
Profit & Loss
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 16.62 | 11.54 | 11.21 | 12.31 | 15.8 | 14.81 | 42.26 |
| Expenses | 15.71 | 10.68 | 10.44 | 9.73 | 14.97 | 14.02 | 39.06 |
| Operating Profit | 0.91 | 0.86 | 0.77 | 2.58 | 0.83 | 0.79 | 3.2 |
| OPM % | 5.48% | 7.45% | 6.87% | 20.96% | 5.25% | 5.33% | 7.57% |
| Other Income | 0.01 | 0 | 0 | 0.02 | 0.32 | 0.47 | 0 |
| Interest | 0.41 | 0.44 | 0.51 | 0.65 | 0.79 | 0.85 | 0.07 |
| Depreciation | 0.31 | 0.26 | 0.22 | 0.17 | 0.13 | 0.1 | 0.28 |
| PBT | 0.2 | 0.16 | 0.04 | 1.78 | 0.23 | 0.31 | 2.85 |
| Tax % | 20% | 25% | 25% | 30.34% | 26.09% | 25.81% | 31.93% |
| Net Profit | 0.16 | 0.12 | 0.03 | 1.25 | 0.16 | 0.22 | 1.93 |
| EPS in Rs | 0.48 | 0.36 | 0.09 | 1.26 | 0.11 | 0.16 | 1.27 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3.3 | 3.3 | 3.3 | 9.95 | 13.95 | 13.95 | 15.25 |
| Reserves | 3.94 | 4.06 | 4.1 | 0.73 | 8.89 | 9.11 | 13.12 |
| Borrowings | 4.53 | 5.52 | 5.3 | 4.93 | 6.83 | 2.57 | 0.21 |
| Other Liabilities | 2.24 | 1.01 | 0.86 | 2.07 | 2.73 | 2.1 | 6.36 |
| Total Liabilities | 14.01 | 13.89 | 13.56 | 17.68 | 32.4 | 27.73 | 34.94 |
| Fixed Assets | 2.13 | 1.87 | 1.65 | 1.51 | 1.38 | 1.28 | 2.87 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1.57 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 11.88 | 12.02 | 11.91 | 16.17 | 31.02 | 24.88 | 32.07 |
| Total Assets | 14.01 | 13.89 | 13.56 | 17.68 | 32.4 | 27.73 | 34.94 |
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Operating | -1.46 | -1 | 0.21 | -1.66 | -7.42 | 0.22 | 0.7 |
| Investing | -0.02 | 0 | 0 | -0.03 | 0.32 | -1.11 | -0.3 |
| Financing | 1.51 | 0.98 | -0.22 | 1.68 | 8.87 | -5.1 | 1.01 |
| Net Cash Flow | 0.03 | -0.02 | -0.01 | 0 | 1.77 | -5.99 | 1.41 |
| Free Cash Flow | -1.48 | -1 | 0.21 | -1.69 | -7.42 | -1.35 | 0.4 |
| CFO/OP | -156 | -112 | 29 | -43 | -888 | 37 | 49 |
Ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 160 | 242 | 254 | 166 | 131 | 156 | 138 |
| Inventory Days | 56.13 | 83.17 | 93.82 | 44.74 | 125 | 120 | 70.03 |
| Days Payable | 49.48 | 33.11 | 26.34 | 60.49 | 54.71 | 37.67 | 32.49 |
| Cash Conversion Cycle | 166 | 292 | 321 | 150 | 202 | 237 | 175 |
| Working Capital Days | 111 | 204 | 212 | 45.07 | 76.23 | 195 | 168 |
| ROCE % | — | 4.87% | 4.3% | 17.17% | 4.51% | 4.2% | 10.77% |
Documents
1
Copy of Newspaper Publication
13 Aug - Published newspaper ads for notice of Vilin Bio Med's 20th Annual General Meeting on August 13, 2026. 13 Aug - Published newspaper ads for notice of Vilin Bio Med's 20th Annual General Meeting on August 13, 2026.
2
General Updates
11 Aug - NSE issued no-objection for Chemgenix Laboratories’ amalgamation into Vilin Bio Med on August 10, 2026. 11 Aug - NSE issued no-objection for Chemgenix Laboratories’ amalgamation into Vilin Bio Med on August 10, 2026.
3
Outcome of Board Meeting
10 Aug - Board approved AGM notice, appointed secretarial auditor, and fixed 20th AGM on September 2, 2026. 10 Aug - Board approved AGM notice, appointed secretarial auditor, and fixed 20th AGM on September 2, 2026.
4
Updates
1 Aug - Vilin Bio Med registered as Manufacturer Exporter with Pharmexcil, aiding export expansion. 1 Aug - Vilin Bio Med registered as Manufacturer Exporter with Pharmexcil, aiding export expansion.
5
General Updates
29 Jul - Vilin Bio Med signed an MOU with Ideal Pharma BV on July 29, 2026 for European medicine distribution. 29 Jul - Vilin Bio Med signed an MOU with Ideal Pharma BV on July 29, 2026 for European medicine distribution.
Frequently Asked Questions about Vilin Bio Med Ltd
What does Vilin Bio Med Ltd do?
Incorporated in 2005, Vilin Bio Med Ltd is in the business of manufacturing and selling of pharmaceutical products[1]
Where is Vilin Bio Med Ltd (VILINBIO) listed?
Vilin Bio Med Ltd is listed on the Indian stock exchanges. It is listed on NSE: VILINBIO. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Vilin Bio Med Ltd belong to?
Vilin Bio Med Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Vilin Bio Med Ltd?
Vilin Bio Med Ltd has a market capitalisation of approximately ₹64.97 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Vilin Bio Med Ltd?
The Price-to-Earnings (PE) ratio of Vilin Bio Med Ltd is 33.80. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Vilin Bio Med Ltd?
Over the past 52 weeks, Vilin Bio Med Ltd has traded between a low of ₹18.95 and a high of ₹54.4. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Vilin Bio Med Ltd?
Vilin Bio Med Ltd has a Return on Equity (ROE) of 0.97%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Vilin Bio Med Ltd on Tapetide?
On Tapetide, you can view Vilin Bio Med Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2005, Vilin Bio Med Ltd is in the business of manufacturing and selling of pharmaceutical products[1]